Characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients.
OBJECTIVE
The aim of the study was to identify characteristic clinical features and outcomes of critically ill patients with confirmed severe acute respiratory syndrome (SARS).


METHODS
This retrospective study enrolled all patients admitted to a 12-bed SARS intensive care unit (ICU) in a tertiary care medical center in Taipei between May 15 and July 17, 2003. Patients with positive results of either reverse transcriptase-polymerase chain reaction or antibody to SARS coronavirus were defined as SARS cases and others with negative results as control cases.


RESULTS
Of the 50 patients, 14 had confirmed SARS. Demographics were similar between the 2 groups. The highest leukocyte and neutrophil counts, lactate dehydrogenase, and creatine kinase; positive end-expiratory pressure; and use of corticosteroids, ribavirin, and intravenous immunoglobulin were higher in the SARS group. In contrast, the lowest lymphocyte count and the ratio of Pao(2) to the fraction of inspired oxygen were lower in the SARS group. Of the 15 deaths in the control group, 12 (80%) occurred during the first 2 weeks after ICU admission. However, in the confirmed SARS group, 5 (55.6%) of the 9 deaths occurred within the third or fourth week. This difference in timing between these 2 groups was significant (P = .004).


CONCLUSIONS
In a SARS ICU, patients with a confirmed diagnosis of SARS had significantly different clinical features and timing of mortality from those of the control group.
Lien
Te-Cheng
TC
Department of Respiratory Therapy, Taipei Veterans General Hospital, Taipei 112, Taiwan, ROC.
Sung
Chun-Sung
CS
Lee
Chen-Hsen
CH
Kao
Hsin-Kuo
HK
Huang
Ying-Che
YC
Liu
Cheng-Yi
CY
Perng
Reury-Perng
RP
Wang
Jia-Horng
JH
D000046:Academic Medical Centers; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000627:therapeutic use; D015897:Comorbidity; D004363:Drug Utilization; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D017052:Hospital Mortality; D006801:Humans; D007362:Intensive Care Units / Q000706:statistics & numerical data*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D012121:Respiration, Artificial; D012189:Retrospective Studies; D045169:Severe Acute Respiratory Syndrome / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy; D013997:Time Factors
D000890:Anti-Infective Agents; D005938:Glucocorticoids